uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Drotrecogin Alfa (Activated) in Adults with Septic Shock
Show others and affiliations
2012 (English)In: New England Journal of Medicine, ISSN 0028-4793, Vol. 366, no 22, 2055-2064 p.Article in journal (Refereed) Published
Abstract [en]

BACKGROUND There have been conflicting reports on the efficacy of recombinant human activated protein C, or drotrecogin alfa (activated) (DrotAA), for the treatment of patients with septic shock.

METHODS In this randomized, double-blind, placebo-controlled, multicenter trial, we assigned 1697 patients with infection, systemic inflammation, and shock who were receiving fluids and vasopressors above a threshold dose for 4 hours to receive either DrotAA (at a dose of 24 mu g per kilogram of body weight per hour) or placebo for 96 hours. The primary outcome was death from any cause 28 days after randomization.

RESULTS At 28 days, 223 of 846 patients (26.4%) in the DrotAA group and 202 of 834 (24.2%) in the placebo group had died (relative risk in the DrotAA group, 1.09; 95% confidence interval [CI], 0.92 to 1.28; P = 0.31). At 90 days, 287 of 842 patients (34.1%) in the DrotAA group and 269 of 822 (32.7%) in the placebo group had died (relative risk, 1.04; 95% CI, 0.90 to 1.19; P = 0.56). Among patients with severe protein C deficiency at baseline, 98 of 342 (28.7%) in the DrotAA group had died at 28 days, as compared with 102 of 331 (30.8%) in the placebo group (risk ratio, 0.93; 95% CI, 0.74 to 1.17; P = 0.54). Similarly, rates of death at 28 and 90 days were not significantly different in other predefined subgroups, including patients at increased risk for death. Serious bleeding during the treatment period occurred in 10 patients in the DrotAA group and 8 in the placebo group (P = 0.81).

CONCLUSIONS DrotAA did not significantly reduce mortality at 28 or 90 days, as compared with placebo, in patients with septic shock.

Place, publisher, year, edition, pages
2012. Vol. 366, no 22, 2055-2064 p.
National Category
Medical and Health Sciences
URN: urn:nbn:se:uu:diva-176225DOI: 10.1056/NEJMoa1202290ISI: 000304613400005OAI: oai:DiVA.org:uu-176225DiVA: diva2:535256
Available from: 2012-06-19 Created: 2012-06-18 Last updated: 2012-06-19Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Tenhunen, Jyrki
By organisation
Anaesthesiology and Intensive Care
In the same journal
New England Journal of Medicine
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 286 hits
ReferencesLink to record
Permanent link

Direct link